{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T11:36:05Z","timestamp":1787916965651,"version":"build-2784847793"},"reference-count":200,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AI060530"],"award-info":[{"award-number":["T32AI060530"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32GM136547"],"award-info":[{"award-number":["T32GM136547"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1AI164560"],"award-info":[{"award-number":["UM1AI164560"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI157875"],"award-info":[{"award-number":["K23AI157875"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K23AI162249"],"award-info":[{"award-number":["K23AI162249"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI170239"],"award-info":[{"award-number":["R01AI170239"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01AI178375"],"award-info":[{"award-number":["P01AI178375"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s40265-026-02311-3","type":"journal-article","created":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T04:00:54Z","timestamp":1777694454000},"page":"851-870","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Immune-Based Approaches for the Cure of HIV Infection"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2438-3873","authenticated-orcid":false,"given":"Julia A.","family":"Wagner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4095-2036","authenticated-orcid":false,"given":"Demi A.","family":"Sandel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4722-463X","authenticated-orcid":false,"given":"Amelia N.","family":"Deitchman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3596-059X","authenticated-orcid":false,"given":"Rachel L.","family":"Rutishauser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6371-747X","authenticated-orcid":false,"given":"Steven G.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0585-6230","authenticated-orcid":false,"given":"Michael J.","family":"Peluso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"issue":"3","key":"2311_CR1","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.immuni.2007.08.010","volume":"27","author":"SG Deeks","year":"2007","unstructured":"Deeks SG, Walker BD. Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity. 2007;27(3):406\u201316. https:\/\/doi.org\/10.1016\/j.immuni.2007.08.010.","journal-title":"Immunity"},{"issue":"7","key":"2311_CR2","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"G H\u00fctter","year":"2009","unstructured":"H\u00fctter G, Nowak D, Mossner M, Ganepola S, M\u00fc\u00dfig A, Allers K, et al. Long-term control of HIV by CCR5 delta32\/delta32 stem-cell transplantation. N Engl J Med. 2009;360(7):692\u20138. https:\/\/doi.org\/10.1056\/NEJMoa0802905.","journal-title":"N Engl J Med"},{"issue":"4","key":"2311_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jve.2020.100017","volume":"6","author":"K Dub\u00e9","year":"2020","unstructured":"Dub\u00e9 K, Willenberg L, Dee L, Sylla L, Taylor J, Roebuck C, et al. Re-examining the HIV \u2018functional cure\u2019 oxymoron: time for precise terminology? J Virus Erad. 2020;6(4):100017. https:\/\/doi.org\/10.1016\/j.jve.2020.100017.","journal-title":"J Virus Erad"},{"issue":"10189","key":"2311_CR4","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1016\/S0140-6736(19)30418-0","volume":"393","author":"AJ Rodger","year":"2019","unstructured":"Rodger AJ, Cambiano V, Bruun T, Vernazza P, Collins S, Degen O, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428\u201338. https:\/\/doi.org\/10.1016\/S0140-6736(19)30418-0.","journal-title":"Lancet"},{"issue":"12","key":"2311_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1909512","volume":"382","author":"C Orkin","year":"2020","unstructured":"Orkin C, Arasteh K, Hern\u00e1ndez-Mora MG, Pokrovsky V, Overton ET, Girard PM, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1909512.","journal-title":"N Engl J Med"},{"issue":"1","key":"2311_CR6","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000901","volume":"20","author":"Y Arens","year":"2025","unstructured":"Arens Y, Gulick RM. Future options for long-acting HIV treatment and prevention. Curr Opin HIV AIDS. 2025;20(1):39. https:\/\/doi.org\/10.1097\/COH.0000000000000901.","journal-title":"Curr Opin HIV AIDS"},{"issue":"2","key":"2311_CR7","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s40121-018-0201-6","volume":"7","author":"A Chawla","year":"2018","unstructured":"Chawla A, Wang C, Patton C, Murray M, Punekar Y, de Ruiter A, et al. A review of long-term toxicity of antiretroviral treatment regimens and implications for an aging population. Infect Dis Ther. 2018;7(2):183\u201395. https:\/\/doi.org\/10.1007\/s40121-018-0201-6.","journal-title":"Infect Dis Ther"},{"key":"2311_CR8","volume-title":"Confronting discrimination: overcoming HIV-related stigma and discrimination in health-care settings and beyond","author":"Joint United Nations Programme on HIV\/AIDS (UNAIDS)","year":"2017","unstructured":"Joint United Nations Programme on HIV\/AIDS (UNAIDS). Confronting discrimination: overcoming HIV-related stigma and discrimination in health-care settings and beyond. Geneva: UNAIDS; 2017."},{"issue":"9","key":"2311_CR9","doi-asserted-by":"publisher","first-page":"e1400","DOI":"10.1016\/S2214-109X(24)00236-5","volume":"12","author":"O Stevens","year":"2024","unstructured":"Stevens O, Sabin K, Anderson RL, Garcia SA, Willis K, Rao A, et al. Population size, HIV prevalence, and antiretroviral therapy coverage among key populations in sub-Saharan Africa: collation and synthesis of survey data, 2010\u201323. Lancet Glob Health. 2024;12(9):e1400\u201312. https:\/\/doi.org\/10.1016\/S2214-109X(24)00236-5.","journal-title":"Lancet Glob Health"},{"issue":"1","key":"2311_CR10","doi-asserted-by":"publisher","first-page":"e42","DOI":"10.1016\/S2352-3018(20)30234-4","volume":"8","author":"SR Lewin","year":"2020","unstructured":"Lewin SR, Attoye T, Bansbach C, Doehle B, Dub\u00e9 K, Dybul M, et al. Multi-stakeholder consensus on a target product profile for an HIV cure. Lancet HIV. 2020;8(1):e42-50. https:\/\/doi.org\/10.1016\/S2352-3018(20)30234-4.","journal-title":"Lancet HIV."},{"issue":"10400","key":"2311_CR11","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/S0140-6736(23)00877-2","volume":"402","author":"LN Broyles","year":"2023","unstructured":"Broyles LN, Luo R, Boeras D, Vojnov L. The risk of sexual transmission of HIV in individuals with low-level HIV viraemia: a systematic review. Lancet. 2023;402(10400):464\u201371. https:\/\/doi.org\/10.1016\/S0140-6736(23)00877-2.","journal-title":"Lancet"},{"issue":"1","key":"2311_CR12","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1097\/COH.0000000000000890","volume":"20","author":"DA Sandel","year":"2025","unstructured":"Sandel DA, Rutishauser RL, Peluso MJ. Post-intervention control in HIV immunotherapy trials. Curr Opin HIV AIDS. 2025;20(1):70\u201370. https:\/\/doi.org\/10.1097\/COH.0000000000000890.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"2311_CR13","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/infdis\/jiaf163","volume":"232","author":"V Klastrup","year":"2025","unstructured":"Klastrup V, Gunst JD, Rasmussen TA, Tolstrup M, S\u00f8gaard OS. Factors influencing virologic control during analytical treatment interruptions in HIV cure trials: a pooled analysis of individual-level data. J Infect Dis. 2025;232(1):69\u201378. https:\/\/doi.org\/10.1093\/infdis\/jiaf163.","journal-title":"J Infect Dis"},{"issue":"7","key":"2311_CR14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1038\/s41591-018-0026-6","volume":"24","author":"DJ Colby","year":"2018","unstructured":"Colby DJ, Trautmann L, Pinyakorn S, Leyre L, Pagliuzza A, Kroon E, et al. Rapid HIV RNA rebound after antiretroviral treatment interruption in persons durably suppressed in Fiebig I acute HIV infection. Nat Med. 2018;24(7):923\u20136. https:\/\/doi.org\/10.1038\/s41591-018-0026-6.","journal-title":"Nat Med"},{"issue":"11","key":"2311_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002417","volume":"14","author":"TJ Henrich","year":"2017","unstructured":"Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, et al. HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study. PLoS Med. 2017;14(11):e1002417. https:\/\/doi.org\/10.1371\/journal.pmed.1002417.","journal-title":"PLoS Med"},{"issue":"1","key":"2311_CR16","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1016\/S2352-3018(23)00236-9","volume":"11","author":"D Persaud","year":"2024","unstructured":"Persaud D, Bryson Y, Nelson BS, Tierney C, Cotton MF, Coletti A, et al. HIV-1 reservoir size after neonatal antiretroviral therapy and the potential to evaluate antiretroviral-therapy-free remission (IMPAACT P1115): a phase 1\/2 proof-of-concept study. Lancet HIV. 2024;11(1):e20-30. https:\/\/doi.org\/10.1016\/S2352-3018(23)00236-9.","journal-title":"Lancet HIV."},{"key":"2311_CR17","unstructured":"Persaud D, Colletti A, Nelson BS, et al. ART-free HIV-1 remission in very early treated children: results from IMPAACT P1115. Presented at: Conference on Retroviruses and Opportunistic Infections; 2024; Denver (CO). Available from: https:\/\/www.croiconference.org\/abstract\/art-free-hiv-1-remission-in-very-early-treated-children-results-from-impaact-p1115\/. [Accessed 7 Apr 20257]."},{"issue":"7751","key":"2311_CR18","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41586-019-1027-4","volume":"568","author":"RK Gupta","year":"2019","unstructured":"Gupta RK, Abdul-Jawad S, McCoy LE, Mok HP, Peppa D, Salgado M, et al. HIV-1 remission following CCR5\u039432\/\u039432 haematopoietic stem-cell transplantation. Nature. 2019;568(7751):244\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1027-4.","journal-title":"Nature"},{"key":"2311_CR19","unstructured":"Rubinstein P, P\u00e9rez L, Rondelli D, et al. Sustained HIV remission despite transient rebound viremia after a CCR5\u220632\/\u220632 stem cell transplant. CROI Conference. Available from: https:\/\/www.croiconference.org\/abstract\/3806-2025\/. [Accessed 10 Jun 2025]."},{"issue":"3","key":"2311_CR20","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41591-023-02213-x","volume":"29","author":"BEO Jensen","year":"2023","unstructured":"Jensen BEO, Knops E, Cords L, L\u00fcbke N, Salgado M, Busman-Sahay K, et al. In-depth virological and immunological characterization of HIV-1 cure after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation. Nat Med. 2023;29(3):583\u20137. https:\/\/doi.org\/10.1038\/s41591-023-02213-x.","journal-title":"Nat Med"},{"key":"2311_CR21","unstructured":"Tr\u00f8seid M, Myhre AE, Hanne H et al. HIV remission after allogeneic hematopoietic stem cell transplant from CCR5\u039432\/\u039432 sibling donor. Presented at: Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco (CA). Available from: https:\/\/www.croiconference.org\/abstract\/3818-2025\/. [Accessed 10 Jun 2025]."},{"issue":"7","key":"2311_CR22","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1056\/NEJMc2312556","volume":"390","author":"JK Dickter","year":"2024","unstructured":"Dickter JK, Aribi A, Cardoso AA, Gianella S, Gendzekhadze K, Li S, et al. HIV-1 remission after allogeneic hematopoietic-cell transplantation. N Engl J Med. 2024;390(7):669\u201371. https:\/\/doi.org\/10.1056\/NEJMc2312556.","journal-title":"N Engl J Med"},{"issue":"6","key":"2311_CR23","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.cell.2023.02.030","volume":"186","author":"J Hsu","year":"2023","unstructured":"Hsu J, Besien KV, Glesby MJ, Pahwa S, Coletti A, Warshaw MG, et al. HIV-1 remission and possible cure in a woman after haplo-cord blood transplant. Cell. 2023;186(6):1115-26.e8. https:\/\/doi.org\/10.1016\/j.cell.2023.02.030.","journal-title":"Cell"},{"key":"2311_CR24","doi-asserted-by":"crossref","unstructured":"S\u00e1ez-Ciri\u00f3n A, Mamez AC, Avettand-Fenoel V, et al. Absence of viral rebound for 18 months without antiretrovirals after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells to treat a biphenotypic sarcoma. Presented at: IAS 2023, The 12th IAS Conference on HIV Science; 2023; Brisbane (QLD). Available from: https:\/\/programme.ias2023.org\/Abstract\/Abstract\/?abstractid=5819. [Accessed 10 Jun 2025].","DOI":"10.1038\/s41591-024-03277-z"},{"key":"2311_CR25","unstructured":"Gaebler C, Kor S, Allers K et al. The next Berlin patient: sustained HIV remission surpassing five years without antiretroviral therapy after heterozygous CCR5 WT\/\u039432 allogeneic hematopoietic stem cell transplantation. Presented at: AIDS 2024, The 25th International AIDS Conference; 2024; Berlin. Available from: https:\/\/programme.aids2024.org\/Abstract\/Abstract\/?abstractid=12163. [Accessed 10 Jun 2025]."},{"key":"2311_CR26","unstructured":"Zaegel-Faucher O, Boschi C, Benkouiten S et al. Absence of viral rebound without antiretrovirals after CCR5\u039432\/\u039432 allogeneic hematopoietic stem cell transplantation: a new case of a potential cure of HIV? Presented at: HIV Drug Therapy; 2024; Glasgow. Available from: https:\/\/www.natap.org\/2024\/Glasgow\/GLASGOW_70.htm. [Accessed 10 Jun 2025]."},{"issue":"5","key":"2311_CR27","doi-asserted-by":"publisher","first-page":"319","DOI":"10.7326\/M14-1027","volume":"161","author":"TJ Henrich","year":"2014","unstructured":"Henrich TJ, Hanhauser E, Marty FM, Sirignano MN, Keating S, Lee TH, et al. Antiretroviral-free HIV-1 remission and viral rebound following allogeneic stem cell transplantation: a report of two cases. Ann Intern Med. 2014;161(5):319\u201327. https:\/\/doi.org\/10.7326\/M14-1027.","journal-title":"Ann Intern Med"},{"issue":"6","key":"2311_CR28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/ni.3152","volume":"16","author":"TW Chun","year":"2015","unstructured":"Chun TW, Moir S, Fauci AS. HIV reservoirs as obstacles and opportunities for an HIV cure. Nat Immunol. 2015;16(6):584\u20139. https:\/\/doi.org\/10.1038\/ni.3152.","journal-title":"Nat Immunol"},{"issue":"5","key":"2311_CR29","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/jmp.12613","volume":"51","author":"K Tanaka","year":"2022","unstructured":"Tanaka K, Kim Y, Roche M, Lewin SR. The role of latency reversal in HIV cure strategies. J Med Primatol. 2022;51(5):278\u201383. https:\/\/doi.org\/10.1111\/jmp.12613.","journal-title":"J Med Primatol"},{"issue":"3","key":"2311_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14030232","volume":"14","author":"L Tioka","year":"2025","unstructured":"Tioka L, Diez RC, S\u00f6nnerborg A, van de Klundert MAA. Latency reversing agents and the road to an HIV cure. Pathogens. 2025;14(3):232. https:\/\/doi.org\/10.3390\/pathogens14030232.","journal-title":"Pathogens"},{"issue":"1","key":"2311_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-60001-2","volume":"16","author":"PM Cevaal","year":"2025","unstructured":"Cevaal PM, Kan S, Fisher BM, Moso MA, Tan A, Liu H, et al. Efficient mRNA delivery to resting T cells to reverse HIV latency. Nat Commun. 2025;16(1):4979. https:\/\/doi.org\/10.1038\/s41467-025-60001-2.","journal-title":"Nat Commun"},{"issue":"8","key":"2311_CR32","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01429-20","volume":"95","author":"M Mavigner","year":"2021","unstructured":"Mavigner M, Liao LE, Brooks AD, Ke R, Mattingly C, Schoof N, et al. CD8 lymphocyte depletion enhances the latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed simian immunodeficiency virus-infected Rhesus macaques. J Virol. 2021;95(8):10.1128\/jvi.01429-20. https:\/\/doi.org\/10.1128\/jvi.01429-20.","journal-title":"J Virol"},{"issue":"3","key":"2311_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000844","volume":"19","author":"E Pellaers","year":"2024","unstructured":"Pellaers E, Denis A, Debyser Z. New latency-promoting agents for a block-and-lock functional cure strategy. Curr Opin HIV AIDS. 2024;19(3):95. https:\/\/doi.org\/10.1097\/COH.0000000000000844.","journal-title":"Curr Opin HIV AIDS"},{"issue":"11","key":"2311_CR34","doi-asserted-by":"publisher","first-page":"4077","DOI":"10.1172\/JCI82314","volume":"125","author":"JAM Sung","year":"2015","unstructured":"Sung JAM, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CYK, Garrido C, et al. Dual-affinity re-targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. J Clin Invest. 2015;125(11):4077\u201390. https:\/\/doi.org\/10.1172\/JCI82314.","journal-title":"J Clin Invest"},{"issue":"11","key":"2311_CR35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005233","volume":"11","author":"DD Sloan","year":"2015","unstructured":"Sloan DD, Lam CYK, Irrinki A, Liu L, Tsai A, Pace CS, et al. Targeting HIV reservoir in infected CD4 T cells by dual-affinity re-targeting molecules (DARTs) that bind HIV envelope and recruit cytotoxic T cells. PLoS Pathog. 2015;11(11):e1005233. https:\/\/doi.org\/10.1371\/journal.ppat.1005233.","journal-title":"PLoS Pathog"},{"key":"2311_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-026-68833-2","author":"L Vandekerckhove","year":"2026","unstructured":"Vandekerckhove L, Fox J, Mora-Peris B, Navarro J, Allard SD, Uriel AJ, et al. Safety and biologic activity of a bispecific T cell receptor targeting HIV Gag in males living with HIV: a first-in-human trial. Nat Commun. 2026. https:\/\/doi.org\/10.1038\/s41467-026-68833-2.","journal-title":"Nat Commun"},{"issue":"21","key":"2311_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00793-20","volume":"94","author":"A Dashti","year":"2020","unstructured":"Dashti A, Waller C, Mavigner M, Schoof N, Bar KJ, Shaw GM, et al. SMAC mimetic plus triple-combination bispecific HIVxCD3 retargeting molecules in SHIV.C.CH505-infected, antiretroviral therapy-suppressed Rhesus macaques. J Virol. 2020;94(21):e00793-20. https:\/\/doi.org\/10.1128\/JVI.00793-20.","journal-title":"J Virol"},{"issue":"1","key":"2311_CR38","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/imr.12484","volume":"275","author":"LE McCoy","year":"2017","unstructured":"McCoy LE, Burton DR. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol Rev. 2017;275(1):11\u201320. https:\/\/doi.org\/10.1111\/imr.12484.","journal-title":"Immunol Rev"},{"issue":"10","key":"2311_CR39","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1038\/s41579-023-00914-1","volume":"21","author":"RJ Landovitz","year":"2023","unstructured":"Landovitz RJ, Scott H, Deeks SG. Prevention, treatment and cure of HIV infection. Nat Rev Microbiol. 2023;21(10):657\u201370. https:\/\/doi.org\/10.1038\/s41579-023-00914-1.","journal-title":"Nat Rev Microbiol"},{"key":"2311_CR40","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.76004","volume":"11","author":"C LaMont","year":"2022","unstructured":"LaMont C, Otwinowski J, Vanshylla K, Gruell H, Klein F, Nourmohammad A. Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1. Elife. 2022;11:e76004. https:\/\/doi.org\/10.7554\/eLife.76004.","journal-title":"Elife"},{"issue":"9","key":"2311_CR41","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1084\/jem.20151267","volume":"212","author":"S Bournazos","year":"2015","unstructured":"Bournazos S, DiLillo DJ, Ravetch JV. The role of Fc-Fc\u03b3R interactions in IgG-mediated microbial neutralization. J Exp Med. 2015;212(9):1361\u20139. https:\/\/doi.org\/10.1084\/jem.20151267.","journal-title":"J Exp Med"},{"issue":"5","key":"2311_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050594","volume":"16","author":"BT Mayer","year":"2024","unstructured":"Mayer BT, Zhang L, de Camp AC, Yu C, Sato A, Angier H, et al. Impact of LS mutation on pharmacokinetics of preventive HIV broadly neutralizing monoclonal antibodies: a cross-protocol analysis of 16 clinical trials in people without HIV. Pharmaceutics. 2024;16(5):5. https:\/\/doi.org\/10.3390\/pharmaceutics16050594.","journal-title":"Pharmaceutics"},{"issue":"6","key":"2311_CR43","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1093\/infdis\/jiad595","volume":"229","author":"J Blazkova","year":"2024","unstructured":"Blazkova J, Whitehead EJ, Schneck R, Shi V, Justement JS, Rai MA, et al. Immunologic and virologic parameters associated with human immunodeficiency virus (HIV) DNA reservoir size in people with HIV receiving antiretroviral therapy. J Infect Dis. 2024;229(6):1770\u201380. https:\/\/doi.org\/10.1093\/infdis\/jiad595.","journal-title":"J Infect Dis"},{"issue":"10","key":"2311_CR44","doi-asserted-by":"publisher","DOI":"10.3390\/v15102055","volume":"15","author":"R Yucha","year":"2023","unstructured":"Yucha R, Litchford ML, Fish CS, Yaffe ZA, Richardson BA, Maleche-Obimbo E, et al. Higher HIV-1 Env gp120-specific antibody-dependent cellular cytotoxicity (ADCC) activity is associated with lower levels of defective HIV-1 provirus. Viruses. 2023;15(10):2055. https:\/\/doi.org\/10.3390\/v15102055.","journal-title":"Viruses"},{"issue":"7724","key":"2311_CR45","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/s41586-018-0531-2","volume":"561","author":"P Mendoza","year":"2018","unstructured":"Mendoza P, Gruell H, Nogueira L, Pai JA, Butler AL, Millard K, et al. Combination therapy with anti-HIV-1 antibodies maintains viral suppression. Nature. 2018;561(7724):479\u201384. https:\/\/doi.org\/10.1038\/s41586-018-0531-2.","journal-title":"Nature"},{"issue":"7913","key":"2311_CR46","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/s41586-022-04797-9","volume":"606","author":"MC Sneller","year":"2022","unstructured":"Sneller MC, Blazkova J, Justement JS, Shi V, Kennedy BD, Gittens K, et al. Combination anti-HIV antibodies provide sustained virological suppression. Nature. 2022;606(7913):375\u201381. https:\/\/doi.org\/10.1038\/s41586-022-04797-9.","journal-title":"Nature"},{"key":"2311_CR47","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03247-5","author":"B Julg","year":"2024","unstructured":"Julg B, Walker-Sperling VEK, Wagh K, Aid M, Stephenson KE, Zash R, et al. Safety and antiviral effect of a triple combination of HIV-1 broadly neutralizing antibodies: a phase 1\/2a trial. Nat Med. 2024. https:\/\/doi.org\/10.1038\/s41591-024-03247-5.","journal-title":"Nat Med"},{"issue":"7913","key":"2311_CR48","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1038\/s41586-022-04597-1","volume":"606","author":"C Gaebler","year":"2022","unstructured":"Gaebler C, Nogueira L, Stoffel E, Oliveira TY, Breton G, Millard KG, et al. Prolonged viral suppression with anti-HIV-1 antibody therapy. Nature. 2022;606(7913):368\u201374. https:\/\/doi.org\/10.1038\/s41586-022-04597-1.","journal-title":"Nature"},{"key":"2311_CR49","doi-asserted-by":"publisher","unstructured":"Fumagalli MJ, Kaczynska A, Allombert M, Lopes-Ribeiro \u00c1, Silva MO, Hernandez BJ, et al. Enhanced HIV-1 control after antibody therapy is associated with autologous antibodies and reservoir clearance in the RIO trial. medRxiv; 2025:2025.11.03.25339415. https:\/\/doi.org\/10.1101\/2025.11.03.25339415.","DOI":"10.1101\/2025.11.03.25339415"},{"issue":"7731","key":"2311_CR50","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1038\/s41586-018-0600-6","volume":"563","author":"EN Borducchi","year":"2018","unstructured":"Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, et al. Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys. Nature. 2018;563(7731):360\u20134. https:\/\/doi.org\/10.1038\/s41586-018-0600-6.","journal-title":"Nature"},{"issue":"10","key":"2311_CR51","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41591-023-02570-7","volume":"29","author":"A Dashti","year":"2023","unstructured":"Dashti A, Sukkestad S, Horner AM, Neja M, Siddiqi Z, Waller C, et al. AZD5582 plus SIV-specific antibodies reduce lymph node viral reservoirs in antiretroviral therapy-suppressed macaques. Nat Med. 2023;29(10):2535\u201346. https:\/\/doi.org\/10.1038\/s41591-023-02570-7.","journal-title":"Nat Med"},{"key":"2311_CR52","doi-asserted-by":"publisher","unstructured":"King H, Roederer M, Bolton DL. HIV-1 bNAb vaccinal effect: an underachieving goal? Curr HIV Res. 2025;23(6):414\u201327. https:\/\/doi.org\/10.2174\/011570162X362665250727012610.","DOI":"10.2174\/011570162X362665250727012610"},{"issue":"10","key":"2311_CR53","doi-asserted-by":"publisher","first-page":"6272","DOI":"10.1128\/JVI.79.10.6272-6280.2005","volume":"79","author":"L Gros","year":"2005","unstructured":"Gros L, Dreja H, Fiser AL, Plays M, Pelegrin M, Piechaczyk M. Induction of long-term protective antiviral endogenous immune response by short neutralizing monoclonal antibody treatment. J Virol. 2005;79(10):6272\u201380. https:\/\/doi.org\/10.1128\/JVI.79.10.6272-6280.2005.","journal-title":"J Virol"},{"issue":"8","key":"2311_CR54","doi-asserted-by":"publisher","first-page":"4573","DOI":"10.4049\/jimmunol.176.8.4573","volume":"176","author":"DH Schuurhuis","year":"2006","unstructured":"Schuurhuis DH, van Montfoort N, Ioan-Facsinay A, Jiawan R, Camps M, Nouta J, et al. Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol. 2006;176(8):4573\u201380. https:\/\/doi.org\/10.4049\/jimmunol.176.8.4573.","journal-title":"J Immunol"},{"issue":"6","key":"2311_CR55","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1182\/blood-2009-10-248609","volume":"116","author":"R Ab\u00e8s","year":"2010","unstructured":"Ab\u00e8s R, G\u00e9liz\u00e9 E, Fridman WH, Teillaud JL. Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response. Blood. 2010;116(6):926\u201334. https:\/\/doi.org\/10.1182\/blood-2009-10-248609.","journal-title":"Blood"},{"issue":"5","key":"2311_CR56","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1016\/j.cell.2015.04.016","volume":"161","author":"DJ DiLillo","year":"2015","unstructured":"DiLillo DJ, Ravetch JV. Differential Fc-receptor engagement drives an anti-tumor vaccinal effect. Cell. 2015;161(5):1035\u201345. https:\/\/doi.org\/10.1016\/j.cell.2015.04.016.","journal-title":"Cell"},{"issue":"38","key":"2311_CR57","doi-asserted-by":"publisher","first-page":"10172","DOI":"10.1073\/pnas.1707950114","volume":"114","author":"J Maamary","year":"2017","unstructured":"Maamary J, Wang TT, Tan GS, Palese P, Ravetch JV. Increasing the breadth and potency of response to the seasonal influenza virus vaccine by immune complex immunization. Proc Natl Acad Sci. 2017;114(38):10172\u20137. https:\/\/doi.org\/10.1073\/pnas.1707950114.","journal-title":"Proc Natl Acad Sci"},{"issue":"7838","key":"2311_CR58","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s41586-020-2838-z","volume":"588","author":"S Bournazos","year":"2020","unstructured":"Bournazos S, Corti D, Virgin HW, Ravetch JV. Fc-optimized antibodies elicit CD8 immunity to viral respiratory infection. Nature. 2020;588(7838):485\u201390. https:\/\/doi.org\/10.1038\/s41586-020-2838-z.","journal-title":"Nature"},{"issue":"1","key":"2311_CR59","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.cell.2015.06.026","volume":"162","author":"TT Wang","year":"2015","unstructured":"Wang TT, Maamary J, Tan GS, Bournazos S, Davis CW, Krammer F, et al. Anti-HA glycoforms drive B cell affinity selection and determine influenza vaccine efficacy. Cell. 2015;162(1):160\u20139. https:\/\/doi.org\/10.1016\/j.cell.2015.06.026.","journal-title":"Cell"},{"issue":"1","key":"2311_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s42003-024-06659-8","volume":"7","author":"SW de Taeye","year":"2024","unstructured":"de Taeye SW, Schriek AI, Umotoy JC, Grobben M, Burger JA, Sanders RW, et al. Afucosylated broadly neutralizing antibodies enhance clearance of HIV-1 infected cells through cell-mediated killing. Commun Biol. 2024;7(1):1\u201311. https:\/\/doi.org\/10.1038\/s42003-024-06659-8.","journal-title":"Commun Biol"},{"issue":"6","key":"2311_CR61","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.molmed.2024.10.008","volume":"31","author":"R Dahan","year":"2025","unstructured":"Dahan R, Korman AJ. Fc-optimized checkpoint antibodies for cancer immunotherapy. Trends Mol Med. 2025;31(6):501\u20135. https:\/\/doi.org\/10.1016\/j.molmed.2024.10.008.","journal-title":"Trends Mol Med"},{"issue":"6","key":"2311_CR62","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cell.2014.08.023","volume":"158","author":"S Bournazos","year":"2014","unstructured":"Bournazos S, Klein F, Pietzsch J, Seaman MS, Nussenzweig MC, Ravetch JV. Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell. 2014;158(6):1243\u201353. https:\/\/doi.org\/10.1016\/j.cell.2014.08.023.","journal-title":"Cell"},{"issue":"2","key":"2311_CR63","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.virol.2011.03.012","volume":"415","author":"AS Dugast","year":"2011","unstructured":"Dugast AS, Tonelli A, Berger CT, Ackerman ME, Sciaranghella G, Liu Q, et al. Decreased Fc receptor expression on innate immune cells is associated with impaired antibody-mediated cellular phagocytic activity in chronically HIV-1 infected individuals. Virology. 2011;415(2):160\u20137. https:\/\/doi.org\/10.1016\/j.virol.2011.03.012.","journal-title":"Virology"},{"issue":"11","key":"2311_CR64","doi-asserted-by":"publisher","first-page":"7916","DOI":"10.4049\/jimmunol.179.11.7916","volume":"179","author":"DN Forthal","year":"2007","unstructured":"Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. Fc\u03b3RIIa genotype predicts progression of HIV infection. J Immunol. 2007;179(11):7916\u201323. https:\/\/doi.org\/10.4049\/jimmunol.179.11.7916.","journal-title":"J Immunol"},{"issue":"5","key":"2311_CR65","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1172\/JCI65708","volume":"123","author":"ME Ackerman","year":"2013","unstructured":"Ackerman ME, Crispin M, Yu X, Baruah K, Boesch AW, Harvey DJ, et al. Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity. J Clin Invest. 2013;123(5):2183\u201392. https:\/\/doi.org\/10.1172\/JCI65708.","journal-title":"J Clin Invest"},{"key":"2311_CR66","unstructured":"Avila-Vargas IE, Rodriguez A, Figueroa TR et al. Clinical and virologic outcomes of an ART interruption in treated controllers and non-controllers. Presented at: Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco (CA). Available from: https:\/\/www.croiconference.org\/abstract\/2603-2025\/. [Accessed 11 Jun 2025]."},{"issue":"7646","key":"2311_CR67","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature21435","volume":"543","author":"Y Nishimura","year":"2017","unstructured":"Nishimura Y, Gautam R, Chun TW, Sadjadpour R, Foulds KE, Shingai M, et al. Early antibody therapy can induce long-lasting immunity to SHIV. Nature. 2017;543(7646):559\u201363. https:\/\/doi.org\/10.1038\/nature21435.","journal-title":"Nature"},{"issue":"2","key":"2311_CR68","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41591-019-0747-1","volume":"26","author":"J Niessl","year":"2020","unstructured":"Niessl J, Baxter AE, Mendoza P, Jankovic M, Cohen YZ, Butler AL, et al. Combination anti-HIV-1 antibody therapy is associated with increased virus-specific T cell immunity. Nat Med. 2020;26(2):222\u20137. https:\/\/doi.org\/10.1038\/s41591-019-0747-1.","journal-title":"Nat Med"},{"key":"2311_CR69","doi-asserted-by":"crossref","unstructured":"Lee MJ, Cherrill LR, Zacharopoulou P, Collins S, Fumagalli M, Falaschetti E, et al. Time to HIV rebound after antiretroviral therapy interruption: a double-blind randomised placebo-controlled trial of long-acting broadly neutralising antibodies; the RIO Trial. medRxiv. 2026:2026.02.04.25342277.","DOI":"10.64898\/2026.02.04.25342277"},{"issue":"7557","key":"2311_CR70","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1038\/nature14411","volume":"522","author":"M Caskey","year":"2015","unstructured":"Caskey M, Klein F, Lorenzi JCC, Seaman MS, West AP, Buckley N, et al. 3BNC117 a broadly neutralizing antibody suppresses viremia in HIV-1-infected humans. Nature. 2015;522(7557):487\u201391. https:\/\/doi.org\/10.1038\/nature14411.","journal-title":"Nature"},{"issue":"2","key":"2311_CR71","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1038\/nm.4268","volume":"23","author":"M Caskey","year":"2017","unstructured":"Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals. Nat Med. 2017;23(2):185\u201391. https:\/\/doi.org\/10.1038\/nm.4268.","journal-title":"Nat Med"},{"issue":"10","key":"2311_CR72","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1038\/s41591-021-01509-0","volume":"27","author":"KE Stephenson","year":"2021","unstructured":"Stephenson KE, Julg B, Tan CS, Zash R, Walsh SR, Rolle CP, et al. Safety, pharmacokinetics and antiviral activity of PGT121, a broadly neutralizing monoclonal antibody against HIV-1: a randomized, placebo-controlled, phase 1 clinical trial. Nat Med. 2021;27(10):1718\u201324. https:\/\/doi.org\/10.1038\/s41591-021-01509-0.","journal-title":"Nat Med"},{"issue":"10","key":"2311_CR73","doi-asserted-by":"publisher","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","volume":"6","author":"MR Gaudinski","year":"2019","unstructured":"Gaudinski MR, Houser KV, Doria-Rose NA, Chen GL, Rothwell RSS, Berkowitz N, et al. Safety and pharmacokinetics of broadly neutralizing human monoclonal antibody VRC07\u2013523LS in healthy adults: a phase 1 dose-escalation clinical trial. Lancet HIV. 2019;6(10):e667\u201379. https:\/\/doi.org\/10.1016\/S2352-3018(19)30181-X.","journal-title":"Lancet HIV."},{"issue":"2","key":"2311_CR74","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1093\/infdis\/jiae486","volume":"231","author":"MH Pahus","year":"2025","unstructured":"Pahus MH, Zheng Y, Olefsky M, Gunst JD, Tebas P, Taiwo B, et al. Evaluation and real-world experience of a neutralization susceptibility screening assay for broadly neutralizing anti-HIV-1 antibodies. J Infect Dis. 2025;231(2):424\u201334. https:\/\/doi.org\/10.1093\/infdis\/jiae486.","journal-title":"J Infect Dis"},{"key":"2311_CR75","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02385-3","author":"L Gieselmann","year":"2026","unstructured":"Gieselmann L, DeLaitsch AT, Rohde M, Radford C, Worczinski J, Ashurov A, et al. Identification of a potent V3 glycan site broadly neutralizing antibody targeting an N332gp120 glycan-independent epitope. Nat Immunol. 2026. https:\/\/doi.org\/10.1038\/s41590-025-02385-3.","journal-title":"Nat Immunol"},{"key":"2311_CR76","unstructured":"Edgar J, Elliott T, Lee M, et al. Altered viral kinetics at ATI after dual LS-bNAbs plus ART: a preliminary analysis of RIO Arm B. Conference on Retrviruses and Opportunistic Infections; 2026; Denver (CO). Available from: https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/resources\/2026\/croi2026-abstract-ebook.pdf. [Accessed 2 Mar 2026]."},{"key":"2311_CR77","doi-asserted-by":"crossref","unstructured":"Altaf M, Nel C, Tipoe T, Edgar J, Zacharopoulou P, Srai D, et al. T cell immunity predicts clinical outcomes on stopping antiretroviral treatment after HIV-specific broadly neutralising antibody therapy. medRxiv. 2026:2026.02.02.26345374.","DOI":"10.64898\/2026.02.02.26345374"},{"issue":"11","key":"2311_CR78","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ni845","volume":"3","author":"SA Migueles","year":"2002","unstructured":"Migueles SA, Laborico AC, Shupert WL, Sabbaghian MS, Rabin R, Hallahan CW, et al. HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat Immunol. 2002;3(11):1061\u20138. https:\/\/doi.org\/10.1038\/ni845.","journal-title":"Nat Immunol"},{"issue":"12","key":"2311_CR79","doi-asserted-by":"publisher","first-page":"6959","DOI":"10.1128\/jvi.00531-12","volume":"86","author":"ZM Ndhlovu","year":"2012","unstructured":"Ndhlovu ZM, Proudfoot J, Cesa K, Alvino DM, McMullen A, Vine S, et al. Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol. 2012;86(12):6959\u201369. https:\/\/doi.org\/10.1128\/jvi.00531-12.","journal-title":"J Virol"},{"issue":"5","key":"2311_CR80","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood-2012-06-436295","volume":"121","author":"ZM Ndhlovu","year":"2013","unstructured":"Ndhlovu ZM, Chibnik LB, Proudfoot J, Vine S, McMullen A, Cesa K, et al. High-dimensional immunomonitoring models of HIV-1\u2013specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control. Blood. 2013;121(5):801\u201311. https:\/\/doi.org\/10.1182\/blood-2012-06-436295.","journal-title":"Blood"},{"issue":"7","key":"2311_CR81","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.4049\/jimmunol.1600693","volume":"197","author":"M Angin","year":"2016","unstructured":"Angin M, Wong G, Papagno L, Versmisse P, David A, Bayard C, et al. Preservation of lymphopoietic potential and virus suppressive capacity by CD8+ T cells in HIV-2-infected controllers. J Immunol. 2016;197(7):2787\u201395. https:\/\/doi.org\/10.4049\/jimmunol.1600693.","journal-title":"J Immunol"},{"issue":"8","key":"2311_CR82","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41577-020-0274-9","volume":"20","author":"DR Collins","year":"2020","unstructured":"Collins DR, Gaiha GD, Walker BD. CD8+ T cells in HIV control, cure and prevention. Nat Rev Immunol. 2020;20(8):471\u201382. https:\/\/doi.org\/10.1038\/s41577-020-0274-9.","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2311_CR83","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1097\/COH.0000000000000748","volume":"17","author":"RL Rutishauser","year":"2022","unstructured":"Rutishauser RL, Trautmann L. CD8 + T-cell responses in HIV controllers: potential implications for novel HIV remission strategies. Curr Opin HIV AIDS. 2022;17(5):315\u201324. https:\/\/doi.org\/10.1097\/COH.0000000000000748.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"2311_CR84","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1080\/21645515.2019.1666957","volume":"16","author":"B Korber","year":"2019","unstructured":"Korber B, Fischer W. T cell-based strategies for HIV-1 vaccines. Hum Vaccin Immunother. 2019;16(3):713\u201322. https:\/\/doi.org\/10.1080\/21645515.2019.1666957.","journal-title":"Hum Vaccin Immunother"},{"issue":"6","key":"2311_CR85","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/COH.0000000000000824","volume":"18","author":"GM Borgo","year":"2023","unstructured":"Borgo GM, Rutishauser RL. Generating and measuring effective vaccine-elicited HIV-specific CD8+ T cell responses. Curr Opin HIV AIDS. 2023;18(6):331. https:\/\/doi.org\/10.1097\/COH.0000000000000824.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6","key":"2311_CR86","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/COH.0000000000000765","volume":"17","author":"C Brander","year":"2022","unstructured":"Brander C, Hartigan-O\u2019Connor D. HIV T-cell immunogen design and delivery. Curr Opin HIV AIDS. 2022;17(6):333. https:\/\/doi.org\/10.1097\/COH.0000000000000765.","journal-title":"Curr Opin HIV AIDS"},{"issue":"1","key":"2311_CR87","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/nm1520","volume":"13","author":"P Kiepiela","year":"2007","unstructured":"Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med. 2007;13(1):46\u201353. https:\/\/doi.org\/10.1038\/nm1520.","journal-title":"Nat Med"},{"issue":"1","key":"2311_CR88","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-9-208","volume":"9","author":"B Mothe","year":"2011","unstructured":"Mothe B, Llano A, Ibarrondo J, Daniels M, Miranda C, Zamarre\u00f1o J, et al. Definition of the viral targets of protective HIV-1-specific t cell responses. J Transl Med. 2011;9(1):208. https:\/\/doi.org\/10.1186\/1479-5876-9-208.","journal-title":"J Transl Med"},{"issue":"1","key":"2311_CR89","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-015-0392-5","volume":"13","author":"B Mothe","year":"2015","unstructured":"Mothe B, Hu X, Llano A, Rosati M, Olvera A, Kulkarni V, et al. A human immune data-informed vaccine concept elicits strong and broad t-cell specificities associated with HIV-1 control in mice and macaques. J Transl Med. 2015;13(1):60. https:\/\/doi.org\/10.1186\/s12967-015-0392-5.","journal-title":"J Transl Med"},{"key":"2311_CR90","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.eclinm.2019.05.009","volume":"11","author":"B Mothe","year":"2019","unstructured":"Mothe B, Manzardo C, Sanchez-Bernabeu A, Coll P, Mor\u00f3n-L\u00f3pez S, Puertas MC, et al. Therapeutic vaccination refocuses t-cell responses towards conserved regions of HIV-1 in early treated individuals (BCN 01 study). EClinicalMedicine. 2019;11:65\u201380. https:\/\/doi.org\/10.1016\/j.eclinm.2019.05.009.","journal-title":"EClinicalMedicine"},{"issue":"1","key":"2311_CR91","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-57284-w","volume":"16","author":"L Bail\u00f3n","year":"2025","unstructured":"Bail\u00f3n L, Molt\u00f3 J, Curran A, Cadi\u00f1anos J, Carlos Lopez Bernaldo de Quir\u00f3s J, de Los Santos I, et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines combined with a TLR7 agonist in early-treated HIV-1 infection: a randomized, placebo-controlled phase 2a trial. Nat Commun. 2025;16(1):2146. https:\/\/doi.org\/10.1038\/s41467-025-57284-w.","journal-title":"Nat Commun"},{"issue":"12","key":"2311_CR92","doi-asserted-by":"publisher","first-page":"2611","DOI":"10.1038\/s41591-022-02060-2","volume":"28","author":"L Bail\u00f3n","year":"2022","unstructured":"Bail\u00f3n L, Llano A, Cede\u00f1o S, Escrib\u00e0 T, Ros\u00e1s-Umbert M, Parera M, et al. Safety, immunogenicity and effect on viral rebound of HTI vaccines in early treated HIV-1 infection: a randomized, placebo-controlled phase 1 trial. Nat Med. 2022;28(12):2611\u201321. https:\/\/doi.org\/10.1038\/s41591-022-02060-2.","journal-title":"Nat Med"},{"issue":"3","key":"2311_CR93","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8030360","volume":"8","author":"N Moyo","year":"2020","unstructured":"Moyo N, Wee EG, Korber B, Bahl K, Falcone S, Himansu S, et al. Tetravalent immunogen assembled from conserved regions of HIV-1 and delivered as mRNA demonstrates potent preclinical t-cell immunogenicity and breadth. Vaccines. 2020;8(3):360. https:\/\/doi.org\/10.3390\/vaccines8030360.","journal-title":"Vaccines"},{"key":"2311_CR94","doi-asserted-by":"publisher","unstructured":"Borthwick N, Fernandez N, Hayes PJ, Wee EGT, Yildirim BMA, Baines A, et al. Safety and immunogenicity of the ChAdOx1\u2013MVA-vectored conserved mosaic HIVconsvX candidate T-cell vaccines in HIV-CORE 005.2, an open-label, dose-escalation, first-in-human, phase 1 trial in adults living without HIV-1 in the UK. Lancet Microbe. 2024. https:\/\/doi.org\/10.1016\/j.lanmic.2024.100956.","DOI":"10.1016\/j.lanmic.2024.100956"},{"issue":"7","key":"2311_CR95","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1080\/21645515.2018.1448328","volume":"14","author":"P Munson","year":"2018","unstructured":"Munson P, Liu Y, Bratt D, Fuller JT, Hu X, Pavlakis GN, et al. Therapeutic conserved elements (CE) DNA vaccine induces strong t-cell responses against highly conserved viral sequences during simian-human immunodeficiency virus infection. Hum Vaccines Immunother. 2018;14(7):1820\u201331. https:\/\/doi.org\/10.1080\/21645515.2018.1448328.","journal-title":"Hum Vaccines Immunother"},{"issue":"7","key":"2311_CR96","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003804","volume":"38","author":"JM Jacobson","year":"2024","unstructured":"Jacobson JM, Felber BK, Chen H, Pavlakis GN, Mullins JI, De Rosa SC, et al. The immunogenicity of an HIV-1 Gag conserved element DNA vaccine in people with HIV and receiving antiretroviral therapy. AIDS. 2024;38(7):963. https:\/\/doi.org\/10.1097\/QAD.0000000000003804.","journal-title":"AIDS"},{"key":"2311_CR97","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09929-5","author":"MJ Peluso","year":"2025","unstructured":"Peluso MJ, Sandel DA, Deitchman AN, Kim SJ, Dalhuisen T, Tummala HP, et al. Correlates of HIV-1 control after combination immunotherapy. Nature. 2025. https:\/\/doi.org\/10.1038\/s41586-025-09929-5.","journal-title":"Nature"},{"issue":"6439","key":"2311_CR98","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1126\/science.aav5095","volume":"364","author":"GD Gaiha","year":"2019","unstructured":"Gaiha GD, Rossin EJ, Urbach J, Landeros C, Collins DR, Nwonu C, et al. Structural topology defines protective CD8+ t cell epitopes in the HIV proteome. Science. 2019;364(6439):480\u20134. https:\/\/doi.org\/10.1126\/science.aav5095.","journal-title":"Science"},{"issue":"6","key":"2311_CR99","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000763","volume":"17","author":"T Hanke","year":"2022","unstructured":"Hanke T. New vector and vaccine platforms: mRNA, DNA, viral vectors. Curr Opin HIV AIDS. 2022;17(6):338. https:\/\/doi.org\/10.1097\/COH.0000000000000763.","journal-title":"Curr Opin HIV AIDS"},{"issue":"6676","key":"2311_CR100","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1126\/science.adg0514","volume":"382","author":"SA Migueles","year":"2023","unstructured":"Migueles SA, Nettere DM, Gavil NV, Wang LT, Toulmin SA, Kelly EP, et al. HIV vaccines induce CD8+ t cells with low antigen receptor sensitivity. Science. 2023;382(6676):1270\u20136. https:\/\/doi.org\/10.1126\/science.adg0514.","journal-title":"Science"},{"issue":"31","key":"2311_CR101","doi-asserted-by":"publisher","first-page":"4439","DOI":"10.1016\/j.vaccine.2023.06.029","volume":"41","author":"A Singh","year":"2023","unstructured":"Singh A, Boggiano C, Eller MA, Maciel M, Marovich MA, Mehra VL, et al. Optimizing the immunogenicity of HIV vaccines by adjuvants: NIAID workshop report. Vaccine. 2023;41(31):4439\u201346. https:\/\/doi.org\/10.1016\/j.vaccine.2023.06.029.","journal-title":"Vaccine"},{"issue":"99","key":"2311_CR102","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.adl3755","volume":"9","author":"SH Bhagchandani","year":"2024","unstructured":"Bhagchandani SH, Yang L, Lam JH, Maiorino L, Ben-Akiva E, Rodrigues KA, et al. Two-dose priming immunization amplifies humoral immunity by synchronizing vaccine delivery with the germinal center response. Sci Immunol. 2024;9(99):eadl3755. https:\/\/doi.org\/10.1126\/sciimmunol.adl3755.","journal-title":"Sci Immunol"},{"issue":"7348","key":"2311_CR103","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/nature10003","volume":"473","author":"SG Hansen","year":"2011","unstructured":"Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, et al. Profound early control of highly pathogenic SIV by an effector memory t-cell vaccine. Nature. 2011;473(7348):523\u20137. https:\/\/doi.org\/10.1038\/nature10003.","journal-title":"Nature"},{"issue":"6274","key":"2311_CR104","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1126\/science.aac9475","volume":"351","author":"SG Hansen","year":"2016","unstructured":"Hansen SG, Wu HL, Burwitz BJ, Hughes CM, Hammond KB, Ventura AB, et al. Broadly targeted CD8+ t cell responses restricted by major histocompatibility complex E. Science. 2016;351(6274):714\u201320. https:\/\/doi.org\/10.1126\/science.aac9475.","journal-title":"Science"},{"key":"2311_CR105","doi-asserted-by":"publisher","DOI":"10.1172\/JCI198294","author":"WR Omange","year":"2026","unstructured":"Omange WR, Varco-Merth BD, Fadeyi O, Marenco A, Takata H, Duell DM, et al. Boosting SIV-specific CD8+ t cell responses prior to ART interruption extends time to SIVmac239 rebound. J Clin Invest. 2026. https:\/\/doi.org\/10.1172\/JCI198294.","journal-title":"J Clin Invest"},{"issue":"3","key":"2311_CR106","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/s41577-022-00753-w","volume":"23","author":"BF Haynes","year":"2023","unstructured":"Haynes BF, Wiehe K, Borrow P, Saunders KO, Korber B, Wagh K, et al. Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies. Nat Rev Immunol. 2023;23(3):142\u201358. https:\/\/doi.org\/10.1038\/s41577-022-00753-w.","journal-title":"Nat Rev Immunol"},{"issue":"0","key":"2311_CR107","doi-asserted-by":"publisher","DOI":"10.1126\/science.adr8382","volume":"0","author":"JR Willis","year":"2025","unstructured":"Willis JR, Prabhakaran M, Muthui M, Naidoo A, Sincomb T, Wu W, et al. Vaccination with mRNA-encoded nanoparticles drives early maturation of HIV bnAb precursors in humans. Science. 2025;0(0):eadr8382. https:\/\/doi.org\/10.1126\/science.adr8382.","journal-title":"Science"},{"issue":"1","key":"2311_CR108","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-024-00818-y","volume":"9","author":"M Maciel","year":"2024","unstructured":"Maciel M, Amara RR, Bar KJ, Crotty S, Deeks SG, Duplessis C, et al. Exploring synergies between B- and t-cell vaccine approaches to optimize immune responses against HIV: workshop report. npj Vaccines. 2024;9(1):39. https:\/\/doi.org\/10.1038\/s41541-024-00818-y.","journal-title":"npj Vaccines"},{"issue":"6","key":"2311_CR109","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41591-020-0858-8","volume":"26","author":"PS Arunachalam","year":"2020","unstructured":"Arunachalam PS, Charles TP, Joag V, Bollimpelli VS, Scott MKD, Wimmers F, et al. T cell-inducing vaccine durably prevents mucosal SHIV infection even with lower neutralizing antibody titers. Nat Med. 2020;26(6):932\u201340. https:\/\/doi.org\/10.1038\/s41591-020-0858-8.","journal-title":"Nat Med"},{"issue":"10143","key":"2311_CR110","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/S0140-6736(18)31364-3","volume":"392","author":"DH Barouch","year":"2018","unstructured":"Barouch DH, Tomaka FL, Wegmann F, Stieh DJ, Alter G, Robb ML, et al. Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1\/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). Lancet. 2018;392(10143):232\u201343. https:\/\/doi.org\/10.1016\/S0140-6736(18)31364-3.","journal-title":"Lancet"},{"issue":"4","key":"2311_CR111","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1093\/infdis\/jiy212","volume":"218","author":"LR Baden","year":"2018","unstructured":"Baden LR, Walsh SR, Seaman MS, Cohen YZ, Johnson JA, Licona JH, et al. First-in-human randomized, controlled trial of mosaic HIV-1 immunogens delivered via a modified vaccinia Ankara vector. J Infect Dis. 2018;218(4):633\u201344. https:\/\/doi.org\/10.1093\/infdis\/jiy212.","journal-title":"J Infect Dis"},{"issue":"4","key":"2311_CR112","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41591-020-0774-y","volume":"26","author":"DJ Colby","year":"2020","unstructured":"Colby DJ, Sarnecki M, Barouch DH, Tipsuk S, Stieh DJ, Kroon E, et al. Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption. Nat Med. 2020;26(4):498\u2013501. https:\/\/doi.org\/10.1038\/s41591-020-0774-y.","journal-title":"Nat Med"},{"key":"2311_CR113","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2024.114344","author":"T Mdluli","year":"2024","unstructured":"Mdluli T, Slike BM, Curtis DJ, Shubin Z, Tran U, Li Y, et al. Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption. Cell Rep. 2024. https:\/\/doi.org\/10.1016\/j.celrep.2024.114344.","journal-title":"Cell Rep"},{"key":"2311_CR114","unstructured":"Moraes-Cardoso I, Bail\u00f3n L, Alarc\u00f3n-Soto Y, et al. Safety, immunogenicity, and effect on viral rebound of T\/B-cell vaccines in chronic ART-treated PWH. Conference on Retroviruses and Opportunistic Infections; 2026; Denver (CO). Available from: https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/resources\/2026\/croi2026-abstract-ebook.pdf. [2 Mar 2026]."},{"issue":"1","key":"2311_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41392-023-01522-4","volume":"8","author":"Q Sun","year":"2023","unstructured":"Sun Q, Hong Z, Zhang C, Wang L, Han Z, Ma D. Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. Signal Transduct Target Ther. 2023;8(1):1\u201326. https:\/\/doi.org\/10.1038\/s41392-023-01522-4.","journal-title":"Signal Transduct Target Ther"},{"issue":"22","key":"2311_CR116","doi-asserted-by":"publisher","first-page":"11876","DOI":"10.1128\/JVI.01153-09","volume":"83","author":"SA Migueles","year":"2009","unstructured":"Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, et al. Defective human immunodeficiency virus-specific CD8+ T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol. 2009;83(22):11876\u201389. https:\/\/doi.org\/10.1128\/JVI.01153-09.","journal-title":"J Virol"},{"issue":"12","key":"2311_CR117","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1097\/QAD.0000000000000314","volume":"28","author":"LR Cockerham","year":"2014","unstructured":"Cockerham LR, Jain V, Sinclair E, Glidden DV, Hartogenesis W, Hatano H, et al. Programmed death-1 expression on CD4+ and CD8+ T cells in treated and untreated HIV disease. AIDS. 2014;28(12):1749. https:\/\/doi.org\/10.1097\/QAD.0000000000000314.","journal-title":"AIDS"},{"issue":"3","key":"2311_CR118","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.136648","volume":"6","author":"RL Rutishauser","year":"2021","unstructured":"Rutishauser RL, Deguit CDT, Hiatt J, Blaeschke F, Roth TL, Wang L, et al. TCF-1 regulates HIV-specific CD8+ T cell expansion capacity. JCI Insight. 2021;6(3):e136648. https:\/\/doi.org\/10.1172\/jci.insight.136648.","journal-title":"JCI Insight"},{"key":"2311_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2022.103840","volume":"76","author":"C Gubser","year":"2022","unstructured":"Gubser C, Chiu C, Lewin SR, Rasmussen TA. Immune checkpoint blockade in HIV. EBioMedicine. 2022;76:103840. https:\/\/doi.org\/10.1016\/j.ebiom.2022.103840.","journal-title":"EBioMedicine"},{"issue":"10","key":"2311_CR120","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1038\/nm1482","volume":"12","author":"L Trautmann","year":"2006","unstructured":"Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat Med. 2006;12(10):1198\u2013202. https:\/\/doi.org\/10.1038\/nm1482.","journal-title":"Nat Med"},{"issue":"11","key":"2311_CR121","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1038\/ni1515","volume":"8","author":"DE Kaufmann","year":"2007","unstructured":"Kaufmann DE, Kavanagh DG, Pereyra F, Zaunders JJ, Mackey EW, Miura T, et al. Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nat Immunol. 2007;8(11):1246\u201354. https:\/\/doi.org\/10.1038\/ni1515.","journal-title":"Nat Immunol"},{"issue":"1","key":"2311_CR122","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4049\/jimmunol.2100367","volume":"208","author":"CY Chiu","year":"2022","unstructured":"Chiu CY, Chang JJ, Dantanarayana AI, Solomon A, Evans VA, Pascoe R, et al. Combination immune checkpoint blockade enhances IL-2 and CD107a production from HIV-specific T cells ex vivo in people living with HIV on Aatiretroviral therapy. J Immunol. 2022;208(1):54\u201362. https:\/\/doi.org\/10.4049\/jimmunol.2100367.","journal-title":"J Immunol"},{"key":"2311_CR123","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.clim.2017.09.002","volume":"183","author":"K Grabmeier-Pfistershammer","year":"2017","unstructured":"Grabmeier-Pfistershammer K, Stecher C, Zettl M, Rosskopf S, Rieger A, Zlabinger GJ, et al. Antibodies targeting BTLA or TIM-3 enhance HIV-1 specific T cell responses in combination with PD-1 blockade. Clin Immunol. 2017;183:167\u201373. https:\/\/doi.org\/10.1016\/j.clim.2017.09.002.","journal-title":"Clin Immunol"},{"issue":"16","key":"2311_CR124","doi-asserted-by":"publisher","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","volume":"187","author":"AR Cillo","year":"2024","unstructured":"Cillo AR, Cardello C, Shan F, Karapetyan L, Kunning S, Sander C, et al. Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8+ T cells to promote antitumor immunity. Cell. 2024;187(16):4373-88.e15. https:\/\/doi.org\/10.1016\/j.cell.2024.06.036.","journal-title":"Cell"},{"issue":"1","key":"2311_CR125","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.immuni.2018.11.014","volume":"50","author":"S Kurtulus","year":"2019","unstructured":"Kurtulus S, Madi A, Escobar G, Klapholz M, Nyman J, Christian E, et al. Checkpoint blockade immunotherapy induces dynamic changes in PD-1\u2212CD8+ tumor-infiltrating T Cells. Immunity. 2019;50(1):181-4.e6. https:\/\/doi.org\/10.1016\/j.immuni.2018.11.014.","journal-title":"Immunity"},{"issue":"7","key":"2311_CR126","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1038\/nm.4113","volume":"22","author":"R Banga","year":"2016","unstructured":"Banga R, Procopio FA, Noto A, Pollakis G, Cavassini M, Ohmiti K, et al. PD-1+ and follicular helper T cells are responsible for persistent HIV-1 transcription in treated aviremic individuals. Nat Med. 2016;22(7):754\u201361. https:\/\/doi.org\/10.1038\/nm.4113.","journal-title":"Nat Med"},{"issue":"7","key":"2311_CR127","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005761","volume":"12","author":"R Fromentin","year":"2016","unstructured":"Fromentin R, Bakeman W, Lawani MB, Khoury G, Hartogensis W, DaFonseca S, et al. CD4+ T cells expressing PD-1, TIGIT and LAG-3 contribute to HIV persistence during ART. PLoS Pathog. 2016;12(7):e1005761. https:\/\/doi.org\/10.1371\/journal.ppat.1005761.","journal-title":"PLoS Pathog"},{"issue":"1","key":"2311_CR128","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-08798-7","volume":"10","author":"R Fromentin","year":"2019","unstructured":"Fromentin R, DaFonseca S, Costiniuk CT, El-Far M, Procopio FA, Hecht FM, et al. PD-1 blockade potentiates HIV latency reversal ex vivo in CD4+ T cells from ART-suppressed individuals. Nat Commun. 2019;10(1):814. https:\/\/doi.org\/10.1038\/s41467-019-08798-7.","journal-title":"Nat Commun"},{"issue":"5","key":"2311_CR129","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.4049\/jimmunol.1901191","volume":"204","author":"RM Van der Sluis","year":"2020","unstructured":"Van der Sluis RM, Kumar NA, Pascoe RD, Zerbato JM, Evans VA, Dantanarayana AI, et al. Combination immune checkpoint blockade to reverse HIV latency. J Immunol. 2020;204(5):1242\u201354. https:\/\/doi.org\/10.4049\/jimmunol.1901191.","journal-title":"J Immunol"},{"issue":"33","key":"2311_CR130","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2202148119","volume":"119","author":"V Velu","year":"2022","unstructured":"Velu V, Titanji K, Ahmed H, Shetty RD, Chennareddi LS, Freeman GJ, et al. PD-1 blockade following ART interruption enhances control of pathogenic SIV in rhesus macaques. Proc Natl Acad Sci U S A. 2022;119(33):e2202148119. https:\/\/doi.org\/10.1073\/pnas.2202148119.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"63","key":"2311_CR131","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abh3034","volume":"6","author":"SA Rahman","year":"2021","unstructured":"Rahman SA, Yagnik B, Bally AP, Morrow KN, Wang S, Vanderford TH, et al. PD-1 blockade and vaccination provide therapeutic benefit against SIV by inducing broad and functional CD8+ T cells in lymphoid tissue. Sci Immunol. 2021;6(63):eabh3034. https:\/\/doi.org\/10.1126\/sciimmunol.abh3034.","journal-title":"Sci Immunol"},{"issue":"11","key":"2311_CR132","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01163-19","volume":"63","author":"E Bekerman","year":"2019","unstructured":"Bekerman E, Hesselgesser J, Carr B, Nagel M, Hung M, Wang A, et al. PD-1 Blockade and TLR7 activation lack therapeutic benefit in chronic simian immunodeficiency virus-infected macaques on antiretroviral therapy. Antimicrob Agents Chemother. 2019;63(11):10.1128\/aac.01163-19. https:\/\/doi.org\/10.1128\/aac.01163-19.","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"2311_CR133","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1038\/s41590-024-01952-4","volume":"25","author":"S Pereira Ribeiro","year":"2024","unstructured":"Pereira Ribeiro S, Strongin Z, Soudeyns H, ten-Caten F, Ghneim K, Pacheco Sanchez G, et al. Dual blockade of IL-10 and PD-1 leads to control of SIV viral rebound following analytical treatment interruption. Nat Immunol. 2024;25(10):1900\u201312. https:\/\/doi.org\/10.1038\/s41590-024-01952-4.","journal-title":"Nat Immunol"},{"issue":"2","key":"2311_CR134","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1093\/annonc\/mdx696","volume":"29","author":"A Guihot","year":"2018","unstructured":"Guihot A, Marcelin AG, Massiani MA, Samri A, Souli\u00e9 C, Autran B, et al. Drastic decrease of the HIV reservoir in a patient treated with nivolumab for lung cancer. Ann Oncol. 2018;29(2):517\u20138. https:\/\/doi.org\/10.1093\/annonc\/mdx696.","journal-title":"Ann Oncol"},{"issue":"10","key":"2311_CR135","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1093\/annonc\/mdy259","volume":"29","author":"EP Scully","year":"2018","unstructured":"Scully EP, Rutishauser RL, Simoneau CR, Delagr\u00e8verie H, Euler Z, Thanh C, et al. Inconsistent HIV reservoir dynamics and immune responses following anti-PD-1 therapy in cancer patients with HIV infection. Ann Oncol. 2018;29(10):2141\u20132. https:\/\/doi.org\/10.1093\/annonc\/mdy259.","journal-title":"Ann Oncol"},{"issue":"7","key":"2311_CR136","doi-asserted-by":"publisher","first-page":"e1973","DOI":"10.1093\/cid\/ciaa1530","volume":"73","author":"TA Rasmussen","year":"2021","unstructured":"Rasmussen TA, Rajdev L, Rhodes A, Dantanarayana A, Tennakoon S, Chea S, et al. Impact of anti-PD-1 and anti-CTLA-4 on the human immunodeficiency virus (HIV) reservoir in people living with HIV with cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study. Clin Infect Dis. 2021;73(7):e1973\u201381. https:\/\/doi.org\/10.1093\/cid\/ciaa1530.","journal-title":"Clin Infect Dis"},{"issue":"10","key":"2311_CR137","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002919","volume":"35","author":"JSY Lau","year":"2021","unstructured":"Lau JSY, McMahon JH, Gubser C, Solomon A, Chiu CYH, Dantanarayana A, et al. The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy. AIDS. 2021;35(10):1631. https:\/\/doi.org\/10.1097\/QAD.0000000000002919.","journal-title":"AIDS"},{"issue":"7","key":"2311_CR138","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1097\/QAD.0000000000001429","volume":"31","author":"G Le Garff","year":"2017","unstructured":"Le Garff G, Samri A, Lambert-Niclot S, Even S, Lavol\u00e9 A, Cadranel J, et al. Transient HIV-specific T cells increase and inflammation in an HIV-infected patient treated with nivolumab. AIDS. 2017;31(7):1048. https:\/\/doi.org\/10.1097\/QAD.0000000000001429.","journal-title":"AIDS"},{"issue":"2","key":"2311_CR139","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/s41591-025-04139-y","volume":"32","author":"A Talla","year":"2026","unstructured":"Talla A, Azevedo JLLC, Latif MB, Enriquez AB, Sanchez GP, Pelletier AN, et al. Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy. Nat Med. 2026;32(2):505\u201317. https:\/\/doi.org\/10.1038\/s41591-025-04139-y.","journal-title":"Nat Med"},{"issue":"11","key":"2311_CR140","doi-asserted-by":"publisher","first-page":"3879","DOI":"10.1038\/s41591-025-03993-0","volume":"31","author":"MN Ramgopal","year":"2025","unstructured":"Ramgopal MN, Lalezari JP, Pires dos Santos AG, Krishnan P, Vaidya TR, Zhou F, et al. Budigalimab, an anti-PD-1 inhibitor, for people living with HIV-1: a randomized, placebo-controlled phase 1b study. Nat Med. 2025;31(11):3879\u201388. https:\/\/doi.org\/10.1038\/s41591-025-03993-0.","journal-title":"Nat Med"},{"key":"2311_CR141","unstructured":"Mothe B, Pires dos Santos AG, Lalezari J, et al. Immune-mediated viral control with budigalimab \u00b1 trosunilimab: first results of phase II global RCT. Conference on Retroviruses and Opportunisitic Infections; 2026; Denver (CO). Available from: https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/resources\/2026\/croi2026-abstract-ebook.pdf. [Accessed 2 Mar 2026]."},{"key":"2311_CR142","doi-asserted-by":"crossref","unstructured":"Govindaraj S, Babu H, Ali S et al. IL-15\/IL-15RA cytokine therapy enhances control of viral rebound in SIV-infected macaques. Presented at: Conference on Retroviruses and Opportunisitic Infections; 2024; Denver (CO). Available from: https:\/\/www.croiconference.org\/abstract\/il-15-il-15ra-cytokine-therapy-enhances-control-of-viral-rebound-in-siv-infected-macaques\/. [Accessed 7 Apr 2025].","DOI":"10.1016\/j.jve.2024.100439"},{"issue":"2","key":"2311_CR143","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1182\/bloodadvances.2017012971","volume":"2","author":"GM Webb","year":"2018","unstructured":"Webb GM, Li S, Mwakalundwa G, Folkvord JM, Greene JM, Reed JS, et al. The human IL-15 superagonist ALT-803 directs SIV-specific CD8+ T cells into B-cell follicles. Blood Adv. 2018;2(2):76\u201384. https:\/\/doi.org\/10.1182\/bloodadvances.2017012971.","journal-title":"Blood Adv"},{"issue":"2","key":"2311_CR144","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1038\/s41591-021-01651-9","volume":"28","author":"JS Miller","year":"2022","unstructured":"Miller JS, Davis ZB, Helgeson E, Reilly C, Thorkelson A, Anderson J, et al. Safety and virologic impact of the IL-15 superagonist N-803 in people living with HIV: a phase 1 trial. Nat Med. 2022;28(2):392\u2013400. https:\/\/doi.org\/10.1038\/s41591-021-01651-9.","journal-title":"Nat Med"},{"key":"2311_CR145","unstructured":"Takata H, Pacheco J, Pinyakorn S et al. RV550: IL-15 superagonist N-803 with ART in acute HIV infection enhances T and NK cell proliferation. Presented at: Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco (CA). Available from: https:\/\/www.croiconference.org\/abstract\/2346-2025-2\/. [Accessed 7 Apr 2025]."},{"key":"2311_CR146","unstructured":"Jones BR, Mar H, Scheck R, et al. A phase I trial of N-803 with or without dual bNAbs to achieve ART-free viral control (ACTG A5386). Presented at: Conference on Retroviruses and Opportunistic Infections; 2026; Denver (CO). Available from: https:\/\/www.croiconference.org\/wp-content\/uploads\/sites\/2\/resources\/2026\/croi2026-abstract-ebook.pdf. [Accessed 2 Mar 2026]."},{"key":"2311_CR147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01112","volume":"11","author":"JT Martinsen","year":"2020","unstructured":"Martinsen JT, Gunst JD, H\u00f8jen JF, Tolstrup M, S\u00f8gaard OS. The use of Toll-like receptor agonists in HIV-1 cure strategies. Front Immunol. 2020;11:1112. https:\/\/doi.org\/10.3389\/fimmu.2020.01112.","journal-title":"Front Immunol"},{"issue":"599","key":"2311_CR148","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abg3071","volume":"13","author":"D SenGupta","year":"2021","unstructured":"SenGupta D, Brinson C, DeJesus E, Mills A, Shalit P, Guo S, et al. The TLR7 agonist vesatolimod induced a modest delay in viral rebound in HIV controllers after cessation of antiretroviral therapy. Sci Transl Med. 2021;13(599):eabg3071. https:\/\/doi.org\/10.1126\/scitranslmed.abg3071.","journal-title":"Sci Transl Med"},{"key":"2311_CR149","unstructured":"Tebas P, Azzoni L, Papasavvas E et al. BEAT2 primary trial outcomes: PEG-IFN-\u03b12b +3BNC117 & 10-1074 in chronic HIV infection. Presented at: Conference on Retroviruses and Opportunistic Infections; 2023; Seattle (WA). Available from: https:\/\/www.croiconference.org\/abstract\/beat2-primary-trial-outcomes-peg-ifn-\u03b12b-3bnc117-10-1074-in-chronic-hiv-infection\/. [Accessed 7 Apr 2025]."},{"issue":"10","key":"2311_CR150","doi-asserted-by":"publisher","first-page":"2547","DOI":"10.1038\/s41591-023-02547-6","volume":"29","author":"JD Gunst","year":"2023","unstructured":"Gunst JD, H\u00f8jen JF, Pahus MH, Ros\u00e1s-Umbert M, Stiksrud B, McMahon JH, et al. Impact of a TLR9 agonist and broadly neutralizing antibodies on HIV-1 persistence: the randomized phase 2a TITAN trial. Nat Med. 2023;29(10):2547\u201358. https:\/\/doi.org\/10.1038\/s41591-023-02547-6.","journal-title":"Nat Med"},{"key":"2311_CR151","unstructured":"Dong K, Asari V, Govender V et al. Evaluation of 2 bNAbs plus vesatolimod in early-treated South African women with HIV-1 during ATI. Presented at: Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco (CA). Available from: https:\/\/www.croiconference.org\/abstract\/2240-2025\/. [cited 2025 Apr 7]."},{"issue":"11","key":"2311_CR152","doi-asserted-by":"publisher","first-page":"2424","DOI":"10.1038\/s41591-022-02023-7","volume":"28","author":"JD Gunst","year":"2022","unstructured":"Gunst JD, Pahus MH, Ros\u00e1s-Umbert M, Lu IN, Benfield T, Nielsen H, et al. Early intervention with 3BNC117 and romidepsin at antiretroviral treatment initiation in people with HIV-1: a phase 1b\/2a, randomized trial. Nat Med. 2022;28(11):2424\u201335. https:\/\/doi.org\/10.1038\/s41591-022-02023-7.","journal-title":"Nat Med"},{"issue":"1","key":"2311_CR153","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34171-2","volume":"13","author":"M Ros\u00e1s-Umbert","year":"2022","unstructured":"Ros\u00e1s-Umbert M, Gunst JD, Pahus MH, Olesen R, Schleimann M, Denton PW, et al. Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity. Nat Commun. 2022;13(1):6473. https:\/\/doi.org\/10.1038\/s41467-022-34171-2.","journal-title":"Nat Commun"},{"issue":"1","key":"2311_CR154","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16219-3","volume":"11","author":"SPM Welten","year":"2020","unstructured":"Welten SPM, Yermanos A, Baumann NS, Wagen F, Oetiker N, Sandu I, et al. Tcf1+ cells are required to maintain the inflationary T cell pool upon MCMV infection. Nat Commun. 2020;11(1):2295. https:\/\/doi.org\/10.1038\/s41467-020-16219-3.","journal-title":"Nat Commun"},{"issue":"5","key":"2311_CR155","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1097\/COH.0000000000000963","volume":"20","author":"MA Moso","year":"2025","unstructured":"Moso MA, Roche M, Cevaal PM, Lewin SR. CRISPR\/Cas9 for achieving postintervention HIV control. Curr Opin HIV AIDS. 2025;20(5):432\u201340. https:\/\/doi.org\/10.1097\/COH.0000000000000963.","journal-title":"Curr Opin HIV AIDS"},{"issue":"5","key":"2311_CR156","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/s41434-023-00410-4","volume":"31","author":"TH Burdo","year":"2024","unstructured":"Burdo TH, Chen C, Kaminski R, Sariyer IK, Mancuso P, Donadoni M, et al. Preclinical safety and biodistribution of CRISPR targeting SIV in non-human primates. Gene Ther. 2024;31(5):224\u201333. https:\/\/doi.org\/10.1038\/s41434-023-00410-4.","journal-title":"Gene Ther"},{"key":"2311_CR157","unstructured":"Presti R. EBT-101: First-in-human clinical trial of systemic CRISPR-CA9 multiplex targeting of latent HIV. Presented at: The American Society of Gene & Cell Therapy Annual Meeting; 2024; Baltimore (MD)."},{"issue":"6","key":"2311_CR158","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0158294","volume":"11","author":"JK Bialek","year":"2016","unstructured":"Bialek JK, Dunay GA, Voges M, Sch\u00e4fer C, Spohn M, Stucka R, et al. Targeted HIV-1 latency reversal using CRISPR\/Cas9-derived transcriptional activator systems. PLoS ONE. 2016;11(6):e0158294. https:\/\/doi.org\/10.1371\/journal.pone.0158294.","journal-title":"PLoS ONE"},{"issue":"10","key":"2311_CR159","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1056\/NEJMoa1300662","volume":"370","author":"P Tebas","year":"2014","unstructured":"Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, et al. Gene editing of CCR5 in autologous CD4 T cells of persons infected with HIV. N Engl J Med. 2014;370(10):901\u201310. https:\/\/doi.org\/10.1056\/NEJMoa1300662.","journal-title":"N Engl J Med"},{"key":"2311_CR160","unstructured":"Fichtenbaum CJ, Bosch RJ, Mar H et al. Infusion of autologous CCR5-deleted CD4 cells does not change the HIV reservoir: the TRAILBLAZER RCT. Presented at: Conference on Retroviruses and Opportunistic Infections; 2025; San Francisco (CA). Available from: https:\/\/www.croiconference.org\/abstract\/3715-2025\/. [Accessed 7 Apr 2025]."},{"issue":"3","key":"2311_CR161","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nm.3471","volume":"20","author":"AB Balazs","year":"2014","unstructured":"Balazs AB, Ouyang Y, Hong CM, Chen J, Nguyen SM, Rao DS, et al. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat Med. 2014;20(3):296\u2013300. https:\/\/doi.org\/10.1038\/nm.3471.","journal-title":"Nat Med"},{"issue":"8","key":"2311_CR162","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/nm.1967","volume":"15","author":"PR Johnson","year":"2009","unstructured":"Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med. 2009;15(8):901\u20136. https:\/\/doi.org\/10.1038\/nm.1967.","journal-title":"Nat Med"},{"issue":"16","key":"2311_CR163","doi-asserted-by":"publisher","first-page":"8334","DOI":"10.1128\/JVI.00908-15","volume":"89","author":"KO Saunders","year":"2015","unstructured":"Saunders KO, Wang L, Joyce MG, Yang ZY, Balazs AB, Cheng C, et al. Broadly neutralizing Human Immunodeficiency Virus Type 1 antibody gene transfer protects nonhuman primates from mucosal Simian-Human Immunodeficiency Virus infection. J Virol. 2015;89(16):8334\u201345. https:\/\/doi.org\/10.1128\/JVI.00908-15.","journal-title":"J Virol"},{"issue":"12","key":"2311_CR164","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1007395","volume":"14","author":"HC Welles","year":"2018","unstructured":"Welles HC, Jennewein MF, Mason RD, Narpala S, Wang L, Cheng C, et al. Vectored delivery of anti-SIV envelope targeting mAb via AAV8 protects Rhesus macaques from repeated limiting dose intrarectal swarm SIVsmE660 challenge. PLoS Pathog. 2018;14(12):e1007395. https:\/\/doi.org\/10.1371\/journal.ppat.1007395.","journal-title":"PLoS Pathog"},{"issue":"8082","key":"2311_CR165","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1038\/s41586-025-09330-2","volume":"645","author":"A Ardeshir","year":"2025","unstructured":"Ardeshir A, O\u2019Hagan D, Mehta I, Shandilya S, Hopkins LLJ, Adamson L, et al. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025;645(8082):1020\u20138. https:\/\/doi.org\/10.1038\/s41586-025-09330-2.","journal-title":"Nature"},{"issue":"5","key":"2311_CR166","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1038\/s41591-022-01762-x","volume":"28","author":"JP Casazza","year":"2022","unstructured":"Casazza JP, Cale EM, Narpala S, Yamshchikov GV, Coates EE, Hendel CS, et al. Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial. Nat Med. 2022;28(5):1022\u201330. https:\/\/doi.org\/10.1038\/s41591-022-01762-x.","journal-title":"Nat Med"},{"issue":"4","key":"2311_CR167","doi-asserted-by":"publisher","first-page":"e230","DOI":"10.1016\/S2352-3018(19)30003-7","volume":"6","author":"FH Priddy","year":"2019","unstructured":"Priddy FH, Lewis DJM, Gelderblom HC, Hassanin H, Streatfield C, LaBranche C, et al. Adeno-associated virus vectored immunoprophylaxis to prevent HIV in healthy adults: a phase 1 randomised controlled trial. Lancet HIV. 2019;6(4):e230\u20139. https:\/\/doi.org\/10.1016\/S2352-3018(19)30003-7.","journal-title":"Lancet HIV."},{"issue":"3","key":"2311_CR168","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.ymthe.2019.01.004","volume":"27","author":"MR Gardner","year":"2019","unstructured":"Gardner MR, Fetzer I, Kattenhorn LM, Davis-Gardner ME, Zhou AS, Alfant B, et al. Anti-drug antibody responses impair prophylaxis mediated by AAV-delivered HIV-1 broadly neutralizing antibodies. Mol Ther. 2019;27(3):650\u201360. https:\/\/doi.org\/10.1016\/j.ymthe.2019.01.004.","journal-title":"Mol Ther"},{"issue":"7971","key":"2311_CR169","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","volume":"619","author":"DJ Baker","year":"2023","unstructured":"Baker DJ, Arany Z, Baur JA, Epstein JA, June CH. CAR T therapy beyond cancer: the evolution of a living drug. Nature. 2023;619(7971):707\u201315. https:\/\/doi.org\/10.1038\/s41586-023-06243-w.","journal-title":"Nature"},{"issue":"2","key":"2311_CR170","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1182\/blood.V96.2.467","volume":"96","author":"RE Walker","year":"2000","unstructured":"Walker RE, Bechtel CM, Natarajan V, Baseler M, Hege KM, Metcalf JA, et al. Long-term in vivo survival of receptor-modified syngeneic T cells in patients with human immunodeficiency virus infection. Blood. 2000;96(2):467\u201374. https:\/\/doi.org\/10.1182\/blood.V96.2.467.","journal-title":"Blood"},{"issue":"3","key":"2311_CR171","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1182\/blood.V96.3.785","volume":"96","author":"RT Mitsuyasu","year":"2000","unstructured":"Mitsuyasu RT, Anton PA, Deeks SG, Scadden DT, Connick E, Downs MT, et al. Prolonged survival and tissue trafficking following adoptive transfer of CD4\u03b6 gene-modified autologous CD4+ and CD8+ T cells in human immunodeficiency virus\u2013infected subjects. Blood. 2000;96(3):785\u201393. https:\/\/doi.org\/10.1182\/blood.V96.3.785.","journal-title":"Blood"},{"key":"2311_CR172","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000001017","author":"K DeLucas","year":"2026","unstructured":"DeLucas K, Blankson JN, Rutishauser RL. Recapitulating the qualities of HIV-specific CD8+ T cells from spontaneous controllers. Curr Opin HIV AIDS. 2026. https:\/\/doi.org\/10.1097\/COH.0000000000001017.","journal-title":"Curr Opin HIV AIDS"},{"issue":"3","key":"2311_CR173","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale M, Mesojednik T, Ibarra GSR, Sahni J, Bernard A, Sommer K, et al. Engineering HIV-resistant, Anti-HIV chimeric antigen receptor T cells. Mol Ther. 2017;25(3):570\u20139. https:\/\/doi.org\/10.1016\/j.ymthe.2016.12.023.","journal-title":"Mol Ther"},{"key":"2311_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2016.56","author":"GSR Ibarra","year":"2016","unstructured":"Ibarra GSR, Paul B, Sather BD, Younan PM, Sommer K, Kowalski JP, et al. Efficient modification of the CCR5 locus in primary human T cells with megaTAL nuclease establishes HIV-1 resistance. Mol Ther Nucleic Acids. 2016. https:\/\/doi.org\/10.1038\/mtna.2016.56.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2311_CR175","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1182\/blood-2013-08-521229","volume":"123","author":"CA Didigu","year":"2014","unstructured":"Didigu CA, Wilen CB, Wang J, Duong J, Secreto AJ, Danet-Desnoyers GA, et al. Simultaneous zinc-finger nuclease editing of the HIV coreceptors ccr5 and cxcr4 protects CD4+ T cells from HIV-1 infection. Blood. 2014;123(1):61\u20139. https:\/\/doi.org\/10.1182\/blood-2013-08-521229.","journal-title":"Blood"},{"issue":"5","key":"2311_CR176","doi-asserted-by":"publisher","DOI":"10.3390\/v15051126","volume":"15","author":"AM Buck","year":"2023","unstructured":"Buck AM, Deveau TM, Henrich TJ, Deitchman AN. Challenges in HIV-1 latent reservoir and target cell quantification in CAR-T cell and other lentiviral gene modifying HIV cure srategies. Viruses. 2023;15(5):1126. https:\/\/doi.org\/10.3390\/v15051126.","journal-title":"Viruses"},{"issue":"3","key":"2311_CR177","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.101033","volume":"297","author":"N Anikeeva","year":"2021","unstructured":"Anikeeva N, Panteleev S, Mazzanti NW, Terai M, Sato T, Sykulev Y. Efficient killing of tumor cells by CAR-T cells requires greater number of engaged CARs than TCRs. J Biol Chem. 2021;297(3):101033. https:\/\/doi.org\/10.1016\/j.jbc.2021.101033.","journal-title":"J Biol Chem"},{"issue":"2","key":"2311_CR178","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41591-021-01621-1","volume":"28","author":"J Mansilla-Soto","year":"2022","unstructured":"Mansilla-Soto J, Eyquem J, Haubner S, Hamieh M, Feucht J, Paillon N, et al. HLA-independent T cell receptors for targeting tumors with low antigen density. Nat Med. 2022;28(2):345\u201352. https:\/\/doi.org\/10.1038\/s41591-021-01621-1.","journal-title":"Nat Med"},{"issue":"504","key":"2311_CR179","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aav5685","volume":"11","author":"K Anthony-Gonda","year":"2019","unstructured":"Anthony-Gonda K, Bardhi A, Ray A, Flerin N, Li M, Chen W, et al. Multispecific anti-HIV duoCAR-T cells display broad in vitro antiviral activity and potent in vivo elimination of HIV-infected cells in a humanized mouse model. Sci Transl Med. 2019;11(504):eaav5685. https:\/\/doi.org\/10.1126\/scitranslmed.aav5685.","journal-title":"Sci Transl Med"},{"issue":"1","key":"2311_CR180","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28727-5","volume":"13","author":"DR Beckford-Vera","year":"2022","unstructured":"Beckford-Vera DR, Flavell RR, Seo Y, Martinez-Ortiz E, Aslam M, Thanh C, et al. First-in-human immunoPET imaging of HIV-1 infection using 89Zr-labeled VRC01 broadly neutralizing antibody. Nat Commun. 2022;13(1):1219. https:\/\/doi.org\/10.1038\/s41467-022-28727-5.","journal-title":"Nat Commun"},{"key":"2311_CR181","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00020","volume":"9","author":"MP Bronnimann","year":"2018","unstructured":"Bronnimann MP, Skinner PJ, Connick E. The B-cell follicle in HIV infection: barrier to a cure. Front Immunol. 2018;9:20. https:\/\/doi.org\/10.3389\/fimmu.2018.00020.","journal-title":"Front Immunol"},{"issue":"5","key":"2311_CR182","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1016\/j.ymthe.2024.02.030","volume":"32","author":"JK Bui","year":"2024","unstructured":"Bui JK, Starke CE, Poole NH, Rust BJ, Jerome KR, Kiem HP, et al. CD20 CAR T cells safely and reversibly ablate B cell follicles in a non-human primate model of HIV persistence. Mol Ther. 2024;32(5):1238\u201351. https:\/\/doi.org\/10.1016\/j.ymthe.2024.02.030.","journal-title":"Mol Ther"},{"issue":"2","key":"2311_CR183","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1009831","volume":"18","author":"MS Pampusch","year":"2022","unstructured":"Pampusch MS, Abdelaal HM, Cartwright EK, Molden JS, Davey BC, Sauve JD, et al. CAR\/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection. PLoS Pathog. 2022;18(2):e1009831. https:\/\/doi.org\/10.1371\/journal.ppat.1009831.","journal-title":"PLoS Pathog"},{"key":"2311_CR184","doi-asserted-by":"publisher","DOI":"10.1172\/JCI150211","author":"B Liu","year":"2021","unstructured":"Liu B, Zhang W, Xia B, Jing S, Du Y, Zou F, et al. Broadly neutralizing antibody\u2013derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J Clin Invest. 2021. https:\/\/doi.org\/10.1172\/JCI150211.","journal-title":"J Clin Invest"},{"issue":"1","key":"2311_CR185","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao Y, Liao Q, Zhu Y, Bi M, Zou J, Zheng N, et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a Phase I, multicenter, single-arm, open-label study. Cell Discov. 2024;10(1):1\u201316. https:\/\/doi.org\/10.1038\/s41421-024-00658-z.","journal-title":"Cell Discov"},{"issue":"1","key":"2311_CR186","doi-asserted-by":"publisher","DOI":"10.1186\/1742-4690-5-112","volume":"5","author":"WB Dyer","year":"2008","unstructured":"Dyer WB, Zaunders JJ, Yuan FF, Wang B, Learmont JC, Geczy AF, et al. Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology. 2008;5(1):112. https:\/\/doi.org\/10.1186\/1742-4690-5-112.","journal-title":"Retrovirology"},{"key":"2311_CR187","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.1044713","volume":"9","author":"N Muvarak","year":"2022","unstructured":"Muvarak N, Li H, Galvin JA, Kumar PN, Pauza CD, Bordon J. Safety and durability of AGT103-T autologous T cell therapy for HIV infection in a Phase 1 trial. Front Med. 2022;9:1044713. https:\/\/doi.org\/10.3389\/fmed.2022.1044713.","journal-title":"Front Med"},{"issue":"Suppl. 1","key":"2311_CR188","doi-asserted-by":"publisher","first-page":"7498","DOI":"10.1182\/blood-2022-165775","volume":"140","author":"DK Sohai","year":"2022","unstructured":"Sohai DK, Keller M, Hanley PJ, Datar A, Reynolds E, Copertino D, et al. Phase I study evaluating outcomes of autologous HIV-specific T cells targeting non-escaped epitopes (HST-NEET) therapy in HIV+ iidividuals on ART (NCT03485963). Blood. 2022;140(Suppl. 1):7498\u20139. https:\/\/doi.org\/10.1182\/blood-2022-165775.","journal-title":"Blood"},{"issue":"3","key":"2311_CR189","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/09540121.2025.2584603","volume":"38","author":"A Ahmed","year":"2026","unstructured":"Ahmed A, Taylor J, Lai JCJ, Lau R, Diunugala SD, Louella M, et al. \u201cIt\u2019s not just HIV anymore\u201d: a qualitative exploration of health, research, community and mental health priorities of long-term survivors of HIV in the United States. AIDS Care. 2026;38(3):506\u201320. https:\/\/doi.org\/10.1080\/09540121.2025.2584603.","journal-title":"AIDS Care"},{"key":"2311_CR190","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00373-X","author":"T Ndung\u2019u","year":"2026","unstructured":"Ndung\u2019u T, Dong KL, Colby DJ, Deeks SG, Cotton MF, Dub\u00e9 K, et al. Recommendations from the 2nd consensus workshop on analytical treatment interruption in HIV research trials. Lancet HIV. 2026. https:\/\/doi.org\/10.1016\/S2352-3018(25)00373-X.","journal-title":"Lancet HIV."},{"issue":"2","key":"2311_CR191","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1093\/jac\/dkab324","volume":"77","author":"P Thoueille","year":"2022","unstructured":"Thoueille P, Choong E, Cavassini M, Buclin T, Decosterd LA. Long-acting antiretrovirals: a new era for the management and prevention of HIV infection. J Antimicrob Chemother. 2022;77(2):290\u2013302. https:\/\/doi.org\/10.1093\/jac\/dkab324.","journal-title":"J Antimicrob Chemother"},{"issue":"1","key":"2311_CR192","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-56116-1","volume":"16","author":"JD Gunst","year":"2025","unstructured":"Gunst JD, Gohil J, Li JZ, Bosch RJ, White CS, Chun TW, et al. Time to HIV viral rebound and frequency of post-treatment control after analytical interruption of antiretroviral therapy: an individual data-based meta-analysis of 24 prospective studies. Nat Commun. 2025;16(1):906. https:\/\/doi.org\/10.1038\/s41467-025-56116-1.","journal-title":"Nat Commun"},{"issue":"9","key":"2311_CR193","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1002\/psp4.12224","volume":"6","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacomet Syst Pharmacol. 2017;6(9):576\u201388. https:\/\/doi.org\/10.1002\/psp4.12224.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"7613","key":"2311_CR194","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/nature18929","volume":"535","author":"JF Scheid","year":"2016","unstructured":"Scheid JF, Horwitz JA, Bar-On Y, Kreider EF, Lu CL, Lorenzi JCC, et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature. 2016;535(7613):556\u201360. https:\/\/doi.org\/10.1038\/nature18929.","journal-title":"Nature"},{"issue":"5","key":"2311_CR195","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16050594","volume":"16","author":"BT Mayer","year":"2024","unstructured":"Mayer BT, Zhang L, deCamp AC, Yu C, Sato A, Angier H, et al. Impact of LS mutation on pharmacokinetics of preventive HIV broadly neutralizing monoclonal antibodies: a cross-protocol analysis of 16 clinical trials in people without HIV. Pharmaceutics. 2024;16(5):594. https:\/\/doi.org\/10.3390\/pharmaceutics16050594.","journal-title":"Pharmaceutics"},{"issue":"S2","key":"2311_CR196","doi-asserted-by":"publisher","first-page":"S79","DOI":"10.1002\/jcph.2141","volume":"62","author":"K Sun","year":"2022","unstructured":"Sun K, Liao MZ. Clinical pharmacology considerations on recombinant adeno-associated virus-based gene therapy. J Clin Pharmacol. 2022;62(S2):S79-94. https:\/\/doi.org\/10.1002\/jcph.2141.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"2311_CR197","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1097\/QAD.0000000000000953","volume":"30","author":"JZ Li","year":"2016","unstructured":"Li JZ, Etemad B, Ahmed H, Aga E, Bosch RJ, Mellors JW, et al. The size of the expressed HIV reservoir predicts timing of viral rebound after treatmentiInterruption. AIDS. 2016;30(3):343\u201353. https:\/\/doi.org\/10.1097\/QAD.0000000000000953.","journal-title":"AIDS"},{"key":"2311_CR198","unstructured":"Gunst JD, St\u00f8vring H, Pahus MH et al. Slope of neutralization curve is best predictor of viral decay response to 3BNC117 at ART initiation. Presented at: Conference on Retroviruses and Opportunistic Infection; 2024; Denver (CO). Available from: https:\/\/www.croiconference.org\/abstract\/slope-of-neutralization-curve-is-best-predictor-of-viral-decay-response-to-3bnc117-at-art-initiation\/. [Accessed 10 Feb 2026]."},{"issue":"9","key":"2311_CR199","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1038\/s41591-022-01953-6","volume":"28","author":"PB Gilbert","year":"2022","unstructured":"Gilbert PB, Huang Y, deCamp AC, Karuna S, Zhang Y, Magaret CA, et al. Neutralization titer biomarker for antibody-mediated prevention of HIV-1 acquisition. Nat Med. 2022;28(9):1924\u201332. https:\/\/doi.org\/10.1038\/s41591-022-01953-6.","journal-title":"Nat Med"},{"key":"2311_CR200","unstructured":"Deitchman AN, Serebryannyy L, Johnston R et al. Effect of broadly neutralizing antibody exposure on HIV rebound following combination immunotherapy. Presented at: Conference on Retroviruses and Opportunistic Infections; 2024; Denver (CO). Available from: https:\/\/www.croiconference.org\/abstract\/effect-of-broadly-neutralizing-antibody-exposure-on-hiv-rebound-following-combination-immunotherapy\/. [Accessed 10 Feb 2026]."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02311-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02311-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T14:40:39Z","timestamp":1778856039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02311-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":200,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2311"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02311-3","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Julia A. Wagner is supported in part through the National Institutes of Health\/National Institute of Allergy and Infectious Diseases\u00a0under Award Number T32AI060530. Demi A. Sandel is supported in part through the National Institutes of Health\/National Institute of General Medical Sciences under Award Number T32GM136547. Additional support was provided by the National Institutes of Health UM1AI164560 (DARE, Steven G. Deeks), K23AI157875 (Michael J. Peluso), K23AI162249 (Amelia N. Deitchman), R01AI170239 (Rachel L. Rutishauser), and P01AI178375 (Rachel L. Rutishauser).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Julia A. Wagner, Demi A. Sandel, Amelia N. Deitchman, Rachel L. Rutishauser have no conflicts of interest that are directly relevant to the content of this article. Michael J. Peluso serves on a DSMB for American Gene Technologies. Steven G. Deeks receives research support from Gilead. He is a member of the scientific advisory board for Tendel. He has consulted for AbbVie and ViiV.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Participation"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"JAW, RLR, SGD, and MJP conceptualized the manuscript. JAW, DAS, AND, and MJP performed the literature search and drafted the manuscript. All authors critically revised the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}